Among those assigned to switch to monotherapy, 18 discontinued their assigned treatment. Of those, 11 reported an increase
in symptoms, six expressed a preference to discontinue, and one experienced hyper-lipidemia. Of the 18 monotherapy-switch
patients who discontinued, 12 returned to their baseline polypharmacy combination, three began a different polypharmacy combination,
one began monotherapy with an agent other than one of the two baseline medications, one began monotherapy with one of the
baseline agents and changed to monotherapy with the second baseline agent after 90 days, and one began to taper one of the
two agents but did not complete the taper after symptom levels increased.